Price
CHART BY
Frequently asked questions
What is Ligand Pharma's market capitalization?
The market capitalization of Ligand Pharma is $5.69B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Ligand Pharma's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Ligand Pharma is 30.53. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Ligand Pharma?
Ligand Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $9.354. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Ligand Pharma's stock?
Currently, 10 analysts cover Ligand Pharma's stock, with a consensus target price of $352.40. Analyst ratings provide insights into the stock's expected performance.
What is Ligand Pharma's revenue over the trailing twelve months?
Over the trailing twelve months, Ligand Pharma reported a revenue of $290.54M.
What is the EBITDA for Ligand Pharma?
Ligand Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $134.37M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Ligand Pharma?
Ligand Pharma has a free cash flow of $131.51M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Ligand Pharma have, and what sector and industry does it belong to?
Ligand Pharma employs approximately 47 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Ligand Pharma's shares?
The free float of Ligand Pharma is 19.45M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $5.69B
- EPS (TTM)
- $9.354
- Free Float
- 19.45M
- P/E ratio (TTM)
- 30.53
- Revenue (TTM)
- $290.54M
- EBITDA (TTM)
- $134.37M
- Free Cashflow (TTM)
- $131.51M
Pricing
- 1D span
- $284.42$286.24
- 52W span
- $161.91$324.99
Analyst Ratings
The price target is $352.40 and the stock is covered by 10 analysts.
Buy
10
Hold
0
Sell
0
Information
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
- Employees
- 47
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- LGND
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet